<DOC>
	<DOCNO>NCT00570128</DOCNO>
	<brief_summary>The purpose study determine whether donepezil HCl effective safe improve cognitive dysfunction exhibit child adolescent Down syndrome . Effectiveness measure rating communication , daily living skill , social skill relationship subject age 10 17 .</brief_summary>
	<brief_title>Evaluating The Efficacy And Safety Of Donepezil Hydrochloride ( Aricept ) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Ages 10 17 year old , weight equal 20kg Male female VABSII/PCRF standard composite score &gt; 55 Diagnosis DS ( trisomy 21 ) document chromosomal analysis ( karyotyping ) . If documentation available screening , karyotyping perform screen lab must document prior baseline visit . Na√Øve approve unapproved cholinesterase inhibitor prefer however , prior use medication allow , provide medication discontinue least 3 month prior screen discontinue lack tolerability efficacy sole purpose enrol subject study . Subjects reside community Must expect complete procedure schedule Screening Baseline visit include efficacy safety parameter . Must speak English verbal able understood time must use form communication , sign , symbol board device supplement his/her communication ability Must parent reliable caregiver agree accompany subject clinic visit , provide information subject require protocol , ensure compliance medication schedule Parent Caregiver must constant reliable informant sufficient contact subject detail knowledge subject 's adaptive behavior order able complete VABSII/PCRF accurately . The individual complete form every visit . Should good general health medical condition consider clinically significant unstable Clinical laboratory value within normal limit abnormality consider clinically significant investigator sponsor Stable Type I ( insulindependent ) Type II diabetes eligible provide monitor regularly prior study ensure adequate glucose control ( fast blood glucose &lt; 140mg/dl glycosylated hemoglobin [ hemoglobin A1c ] &lt; 8 % screening ) . Thyroid disease also may include study provide euthyroid stable treatment least 3 month prior screen . History seizure disorder allow provided subject stable treatment least 3 month seizure within past 6 month . Independent ambulation ambulatory aid ( i.e. , walker cane , wheelchair ) , vision hearing ( eyeglasses and/ hearing aid permissible ) sufficient achieve VABSII/PCRF composite standard score &gt; 55 cooperate examination TOVER . Ages &lt; 10 &gt; 17 year Active clinically significant condition affect absorption , distribution metabolism study medication ( e.g. , inflammatory bowel disease , gastric duodenal ulcer severe lactose intolerance ) Known hypersensitivity piperidine derivative cholinesterase inhibitor Currently receive cholinesterase inhibitor receive 3 month prior screen prior use &gt; 3 month prior screen stop lack efficacy tolerability No reliable parent caregiver , subject , caregiver unwilling unable complete outcome measure fulfill requirement study Clinically significant obstructive pulmonary disease asthma untreated controlled treatment within 3 month prior screen Recent ( less equal 2 year ) hematologic/oncologic disorder ( mild anemia allow ) Evidence active , clinically significant , unstable gastrointestinal , renal , hepatic , endocrine cardiovascular system disease Current DSMIVTR diagnosis Major Depressive Disorder ( MDD ) current primary psychiatric diagnosis DS ( per DSMIV ) Any condition would make subject caregiver , opinion investigator , unsuitable study Unsuitability include female subject begin menstruation thus childbearing potential , may sexually active practice effective mean birth control .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Down Syndrome</keyword>
	<keyword>trisomy 21</keyword>
</DOC>